Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings

Leave a Comment / News / By

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings.